Palatin Technologies, Inc. (PTN) Approaching Release of Topline Data from Phase III Trial of Bremelanotide for Female HSDD
Palatin Technologies, Inc. (NYSE MKT: PTN) is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. The company’s lead product candidate, bremelanotide, is currently in pivotal phase III clinical trials for the treatment of female sexual dysfunction. In early August, Palatin announced completion of reconnect studies related to its eight-month trial evaluating the efficacy and safety of subcutaneous bremelanotide as an on-demand treatment for premenopausal women with hypoactive sexual desire disorder (HSDD). The company is currently awaiting data verification, which it expects to be completed later this month,…